Carfilzomib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), HAS (France) and NICE (England), among others, recommended or restricted carfilzomib, while AIFA (Italy) and CIPM (Spain) did not recommend it.
On the same population the two systems disagree outright: NICE (England) recorded restricted in TA657, while PBAC (Australia) recorded not recommended for “Multiple myeloma”.
Assessment has run over 7.5 years, from 25 May 2016 at HAS (France) to 13 Nov 2023 at CONITEC (Brazil).
CONITEC (Brazil) changed its position: not recommended on 27 Sep 2022, recommended by 13 Nov 2023, after a resubmission.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for carfilzomib, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The programme is broad: 9 distinct indication wordings are recorded for carfilzomib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
6 of these 32 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess carfilzomib, on 25 May 2016; AIFA (Italy) did not open a file until 12 Oct 2022 — a wide spread of 6.4 years between the earliest and latest system to look at it.
The record arrives in waves: 8 separate years each carry two or more decisions, spread across 8 years in total.
10 of the 11 agencies here assessed carfilzomib more than once, PBAC (Australia) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for carfilzomib.
The full ledger for carfilzomib reads 15 recommended, 7 not recommended, 5 restricted and 2 deferred to NICE, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 13 Nov 2023 | tratamento de pacientes com mieloma múltiplo recidivado ou refratário que receberam uma terapia prévia. | incorporated into SUS | source |
| AOTMIT (Poland) | 29 Aug 2023 | programu lekowego „Leczenie chorych na szpiczaka plazmocytowego (ICD-10 C90.0) | not recommended | source |
| NICE (England) | 22 Nov 2022 | NICE TA841 | terminated appraisal | source |
| AIFA (Italy) | 12 Oct 2022 | Kyprolis in associazione con daratumumab e desametasone, è indicato per il trattamento di pazienti adulti con mieloma mu… | not reimbursed for the indication assessed (class C) | source |
| PBAC (Australia) | 2022 | Multiple myeloma | Recommended | source |
27 further decisions for carfilzomib, across 10 agencies, are not shown here. They link to 18 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 32 decisions for carfilzomib from 11 agencies, 2016 to 2023. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.